Trials

Author, YearRandomization Adequate?Allocation Concealment Adequate?Groups Similar at Baseline?Eligibility Criteria Specified?Outcome Assessors Masked?Care Provider Masked?Patient Masked?Reporting of Attrition, Crossovers, Adherence, and Contamination?Loss to Followup and Attrition: Differential/High?Intention-to-Treat Analysis?Quality RatingFunding
Chan, 2007235YesYesYesYesYesUnclearUnclearYes; Unclear; Yes; YesYes; NoYesFairResearch grant
Chan, 2010295YesYesYesYesNoYesYesYes; No; Yes; NoYes; YesYesFairPfizer
Cheung, 201082YesUnclearYesYesUnclearYesYesYes; No; No; NoNo; NoYes, >95% included in ITTFairPfizer
Dahlberg, 200952YesUnclearYesYesYesYesYesNo; No; Yes; NoNo; YesYesFairPfizer
Dequeker, 199860UnclearUnclearYesNoUnclearUnclearYesNo; No; No; NoNo; NoNoFairBoehringer Ingelheim
Dickson, 1991298UnclearUnclearYesYesUnclearYesYesYes; No; No; NoNo; YesNoFairPfizer Ltd.
Emery, 200853YesNoNoYesUnclearYesYesYes; No; Yes; NoYes; YesNoFairPfizer
Feng, 2008116UnclearUnclearYesYesYesYesYesNo; No; Yes; NoUnclear; UnclearNoFairChinese Government
Furst, 200161UnclearUnclearYesYesUnclearUnclearUnclearNo; No; No; NoNo; NoNoFairBoehringer Ingelheim
Goldstein, 200088YesUnclearYesYesUnclearUnclearUnclearNo; No; No; NoNo; NoYesFairGD Searle; Pfizer
Goldstein, 2007254YesYesNoYesYesYesYesYes, No, No, NoYes, NoNoFairTAP pharmaceuticals
Goldstein, 2010253YesYesYesYesYesYesYesYes; No; Yes; NoNo, YesYesFairAstraZeneca
Hawkey, 199663UnclearUnclearYesYesUnclearUnclearUnclearNo; No; No; NoNo; NoUnclearFairNR
Herrero-Beaumont, 2007206YesYesYesYesUnclearYesYesYes; No; Yes; NoNo; YesYesFairRottapharm
Hosie, 199664UnclearUnclearYesYesUnclearUnclearUnclearNo; No; No; NoNo; NoYesFairNR
Kahan, 2009209YesUnclearYesYesYes for radiographs, Unclear for other outcome assessmentYesYesYes; No; Yes; NoNo; Yes (32% at 2 years)YesFairIBSA and Genevrier Laboratories
Kosuwon 2010312YesUnclearYesYesYesYesYesYes; NA; Yes; NoNo; NoYes, >95% included in ITTFairFaculty of Medicine, Khon Kaen University and Bangkok Drug Company
Linden, 199666UnclearUnclearYesYesUnclearUnclearUnclearNo; No; No; NoNo; NoNoFairNR
Mazieres, 2007210YesUnclearYesYesUnclearYesYesYes; No; Yes; NoNo; NoYesFairPierre Fabre Company
McKenna, 1998284UnclearUnclearYesYesUnclearUnclearUnclearNo; No; No; NoNo; NoYesFairNR (Pharmacia)
Messier, 2007213UnclearUnclearNoYesUnclearYesYesYes; No; Yes; NoNo; NoYesFairRexall Sundown
Michel, 2005211YesUnclearYesYesYes for reading radiographs, Unclear for other outcome assessmentYesYesYes; No; Yes; NoNo; YesYesFairNR
Moller, 2010212YesUnclearYesYesUnclearYesYesChondroitin: 9.4%
Placebo: 20%
Yes; NoNoFairBioiberica
Rother, 2007299YesYesYesYesUnclearYesYesYes; Yes; Yes; NoNo; NoYesGoodIDEA AG and McNeall Consumer and Specialty Pharmaceuticals
Rozendaal, 2008207YesYesYesYesYesYesYesYes; No; Yes; NoNo; NoYesGoodErasmus Medical Center
Sandelin, 1997300UnclearUnclearYesYesUnclearYesYesUnclear; No; No; NoUnclear; UnclearYesFairNR
Sawitzke, 2008214
Sawitzke, 2010215
YesYesYesYesYesYesYesYes; No; Yes; NoNo; NoYesGoodNIH
Scheiman, 2006261YesYesNoYesYesYesYesYes, No, No, NoYes, NoYesFairAstraZeneca
Silverstein, 200054YesYesYesYesYesUnclearYesNo; No; No; NoNo; NoNoGoodPharmacia
Simon, 2009301YesYesYesYesYesYesYesYes; No; No; NoNo; NoYesGoodNuvo Research Inc
Temple, 2006183YesNoYesYesNoYesYesYes; No; Yes; NoYes; YesYesFairMcNeil Consumer & Specialty Pharmaceuticals
Tiso, 2010302YesYesYesYesNoNoNoYes; No; No; NoNo; NoYesFairHelm Pharmaceuticals
Tugwell, 2004303YesYesYesYesYesYesYesYes; No; Yes; NoNo; NoYesGoodDimethaid Healthcare Ltd.
Underwood, 200749YesYesYesYesNoNoNoYes; Yes; Yes; YesNo; YesNoFairNHS Health Technology Programme
Valat, 200167UnclearUnclearYesYesUnclearUnclearUnclearNo; No; No; NoNo; NoYesFairNR
Wilkens, 2010208YesYesYesYesUnclearYesYesYes; No; Yes; NoNo; NoYesGoodNorwegian Foundation for Health and Rehabilitation
Wojtulewski, 199668UnclearUnclearYesYesUnclearUnclearUnclearNo; No; No; NoNo; NoYesFairNR
*

Quality ratings for the original 2006 CER available at: Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative Effectiveness Review No.6 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024.). Rockville, MD: Agency for Healthcare Research and Quality, 2006. AHRQ Publication No. 06-EHC009.

NA = not applicable; NR = not reported; NSAID = nonsteroidal antiinflammatory drug; QR = quality result; RA = rheumatoid arthritis

From: Appendix G, Quality Assessment of Trials, Systematic Reviews, and Observational Studies*

Cover of Analgesics for Osteoarthritis
Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet].
Comparative Effectiveness Reviews, No. 38.
Chou R, McDonagh MS, Nakamoto E, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.